Yazar "Trabulus, Sinan" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • [ X ]
    Öğe
    ASSOCIATION OF MULTIPLE PLASMA BIOMARKER LEVELS WITH KIDNEY DISEASE ACTIVITY IN FABRY DISEASE
    (Oxford Univ Press, 2023) Ozcan, Seyda Gul; Atli, Zeynep; Eren, Necmi; Dincer, Mevlut Tamer; Turkmen, Kultigin; Ozer, Hakan; Trabulus, Sinan
    [No abstract available]
  • [ X ]
    Öğe
    Coronary artery calcification progression and long-term cardiovascular outcomes in renal transplant recipients: an analysis by the joint model
    (Oxford Univ Press, 2022) Seyahi, Nurhan; Alagoz, Selma; Atli, Zeynep; Ozcan, Seyda Gul; Tripepi, Giovanni; Bakir, Alev; Trabulus, Sinan
    Background. Compared with the general population, the risk of death is substantially higher in renal transplant recipients than in age- and sex-matched individuals in the general population. In the general population, coronary artery calcification (CAC) predicts all-cause and cardiovascular mortality. In this study we aimed to analyse these relationships in renal transplant recipients. Methods. We examined 178 renal transplant patients in this prospective observational cohort study. We measured CAC with multidetector spiral computed tomography using the Agatston score at multiple time points. Overall, 411 scans were performed in 178 patients over an average 12.8 years follow-up. The clinical endpoint was a composite including all-cause death and non-fatal cardiovascular events. Data analysis was performed by the joint model. Results. During a follow-up of 12.862.4 years, coronary calcification progressed over time (P < 0.001) and the clinical endpoint occurred in 54 patients. In the analysis by the joint model, both the baseline CAC score and the CAC score progression were strongly associated with the incidence rate of the composite event [hazard ratio 1.261 (95% confidence interval 1.119-1.420), P = 0.0001]. [GRAPHICS] Conclusions. CAC at baseline and coronary calcification progression robustly predict the risk of death and cardiovascular events in renal transplant recipients. These findings support the hypothesis that the link between the calcifying arteriopathy of renal transplant patients and clinical end points in these patients is causal in nature.
  • [ X ]
    Öğe
    Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression
    (Baskent Univ, 2024) Sonmez, Ozge; Ozcan, Seyda Gul; Karaca, Cebrail; Atli, Zeynep; Dincer, Mevlut Tamer; Trabulus, Sinan; Seyahi, Nurhan
    Objectives: Induction treatment in renal transplant is associated with better graft survival. However, intensified immunosuppression is known to cause unwanted side effects such as infection and malignancy. Furthermore, the effects of the routine use of immunosuppressants in low -risk kidney transplant recipients are still not clear. In this study, we assessed the first -year safety and efficacy of induction treatment. Materials and Methods: We examined first living donor kidney transplant patients who were on tacrolimusbased immunosuppression therapy. We formed 3 groups according to the induction status: antithymocyte globulin induction, basiliximab induction, and no induction. We collected outcome data on delayed graft function, graft loss, creatinine levels, estimated glomerular filtration rates, acute rejection episodes, hospitalization episodes, and infection episodes, including cytomegalovirus infection and bacterial infections. Results: We examined a total of 126 patients (age 35 +/- 12 years; 65% male). Of them, 25 received antithymocyte globulin, 52 received basiliximab, and 49 did not receive any induction treatment. We did not observe any statistically significant difference among the 3 groups in terms of acute rejection episodes, delayed graft function, and first -year graft loss. The estimated glomerular filtration rates were similar among the groups. Overall bacterial infectious complications and cytomegalovirus infection showed similar prevalence among all groups. Hospitalization was less common in the induction -free group. Conclusions: In low -risk patients, induction -free regimens could be associated with a better safety profile without compromising graft survival. Therefore, induction treatment may be disregarded in first living donor transplant patients who receive tacrolimusbased triple immunosuppression treatment.
  • [ X ]
    Öğe
    SARCOPENIA: AN OVERLOOKED DIAGNOSIS IN KIDNEY TRANSPLANT RECIPIENTS
    (Oxford Univ Press, 2022) Ozcan, Seyda Gul; Sonmez, Ozge; Akman, Zafer; Karaca, Cebrail; Atli, Zeynep; Trabulus, Sinan; Seyahi, Nurhan
    [No abstract available]